ArisGlobal
, a provider of solutions to the life sciences industry, today announced the immediate availability of agSupply™, an integrated IWRS (Interactive Web Response System) and logistics management system thatautomates the tracking of clinical trial supplies throughout the supply chain. Leveraging agSupply, study coordinators and investigators have full control of their company’s patient randomization and clinical supply activity down to the patient level.
Traditional supply chain solutions are not integrated with EDC, ePRO and IWRS systems, often causing significant logistical, reconciliation and assignment challenges that can result in delays in supply shipments or shipments that contain incorrect supplies. Insufficient supply inventories result in trial delays while overages represent costly waste. ArisGlobal’s vision for a cloud-enabled, integrated eClinical platform resolves these issues by designing agSupply as part of a fully unified platform that provides out-of-the-box integration with agCapture™ (EDC) and agOutcomes™ (ePRO) solutions. Study teams benefit from real-time visibility into the supply chain and can plan and conduct monitoring activities more cost effectively and accurately. Role-based, single sign-on (SSO) technology provides secure and easy access to all modules via most smartphones, wireless PDAs, tablets and standard Web browsers.
“From shipment to re-supply, agSupply provides a comprehensive range of capabilities to enable companies to reduce drug wastage and achieve better cost control over their drug, device and material management supply chains,” said Sanjeev Gupta, product manager for ArisGlobal. “In designing this solution, we placed a strong emphasis on configurability, usability and adaptability.”
“agSupply is an easy-to-handle system, which unites all steps needed to monitor, record and coordinate medication logistics in one system. The cooperation with ArisGlobal has been performed to our complete satisfaction and agSupply always met our high expectations," commented Dr. Monika Nuk, CRA, Project Management at QPS Austria GmbH, a full-service contract research organization performing preclinical as well as clinical research. “It allows easy tracking of medication orders, shipments and inventories, and it is a convenient tool to monitor medication supply per study site, per country or for the entire study.”
agSupply offers validated randomization methods, automated inventory control, dispensing and titration management, emergency unblinding capabilities and real-time supply reporting. Configurable workflows and automated re-ordering functionality handle depot-to-depot or depot-to-site shipment orders. Automatically generated orders are transmitted to the supply depot based on parameters set by the user, and can provide shipping recommendations (inventory levels) based on past data. Parameters can be adjusted at any time to match the current inventory, shipment and site requests.
agSupply is part of ArisGlobal’s Total Clinical™ integrated platform of core clinical systems—EDC, ePRO, CTMS, trial disclosure, medical coding and clinical safety—using the latest technology and industry standards. It is available as a cloud-based solution via agOnDemand™, ArisGlobal's proven Software-as-a-Service delivery platform.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.